Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables - Net: 2016-2024

Historic Receivables - Net for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $228.5 million.

  • Collegium Pharmaceutical's Receivables - Net rose 2.40% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 2.40%. This contributed to the annual value of $228.5 million for FY2024, which is 27.30% up from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Receivables - Net is $228.5 million, which was up 27.30% from $179.5 million recorded in FY2023.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables - Net peaked at $228.5 million during FY2024, and registered a low of $83.3 million during FY2020.
  • Its 3-year average for Receivables - Net is $197.1 million, with a median of $183.1 million in 2022.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Receivables - Net soared by 73.01% in 2022, and later fell by 1.96% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables - Net (Yearly) stood at $83.3 million in 2020, then climbed by 27.03% to $105.8 million in 2021, then surged by 73.01% to $183.1 million in 2022, then declined by 1.96% to $179.5 million in 2023, then rose by 27.30% to $228.5 million in 2024.